CADL - After Brain Cancer Data Candel Therapeutics' Shares Good News From Pancreatic Cancer Study | Benzinga
Thursday, Candel Therapeutics Inc (NASDAQ:CADL) released updated interim survival data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma.
Survival data were updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy Annual Meeting.
Also Read: Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy.
Data Highlights as of March 29, 2024, Data Cut-off, Include:
Prolonged and sustained survival was observed after experimental treatment with ...